Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit

Atherosclerosis

Volumn 136, Issue 1, 1998, Pages 125-131

  Panagiotopoulos, Sianna ^a   O'Brien, Richard C ^b   Bucala, Richard ^c   Mark E Cooper, ^a   Jerums, George ^a  

^a AUSTIN HEALTH   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

Aminoguanidine; Atherosclerosis; Cholesterol; Glycation

Indexed keywords

AMINOGUANIDINE; CHOLESTEROL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DIETARY INTAKE; FAT INTAKE; GLYCATION; LIPID BLOOD LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; TREATMENT OUTCOME;

ANIMALS; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, DIETARY; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; LIPIDS; MALE; PILOT PROJECTS; RABBITS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0031827123     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00192-5     Document Type: Article

References (55)

1. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 318:1988;1315-1321.
2. Makita Z., Bucala R., Rayfield E.J., Friedman E., Kaufman A.M., Korbet S.M., Barth R.H., Winston J.A., Fuh H., Manogue K.R., Cerami A., Vlassara H. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 343:1994;1519-1522.
3. Brownlee M., Vlassara H., Kooney A., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 232:1986;1629-1632.
4. Wautier J.-L., Wautier M.-P., Schmidt A.-M., Anderson G.M., Hori O., Zoukourian C., Capron L., Chappey O., Yan S.-D., Brett J., Guillausseau P.-J., Stern D. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA. 91:1994;7742-7746.
5. Vlassara H., Moldawer L., Chan B. Macrophage/monocyte receptor for nonenzymatic glycosylated proteins is upregulated by cachectin/tumor necrosis factor. J Clin Invest. 84:1989;1813-1820.
6. Schnider S.L., Kohn R.R. Glycosylation of human collagen in aging and diabetes mellitus. J Clin Invest. 66:1980;1179-1181.
7. Esposito C., Gerlach H., Brett J., Stern D., Vlassara H. Endothelial receptor mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med. 170:1989;1387-1407.
8. Hogan M., Cerami A., Bucala R. Advanced glycosylation endproducts block the anti-proliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest. 90:1992;1110-1115.
9. Gilcrease M.Z., Hoover R.L. Secretion of a chemotactic substance(s) by AGE stimulated human monocytes. Diabetes Res Clin Pract. 16:1992;7-11.
10. Kirstein M., Brett J., Radoff S., Ogawa S., Stern D., Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA. 87:1992;9010-9014.
11. Vlassara H., Fuh H., Donnelly T., Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1:1995;447-456.
12. Schmidt A.M., Hori O., Chen X.J., Li J.F., Crandall J., Zhang J.H., Cao R., Yan S.D., Brett J., Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice - a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 96:1995;1395-1403.
13. Brownlee M., Vlassara H., Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes. 34:1985;938-941.
14. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA. 90:1993;6434-6438.
15. Bowie A., Owens D., Collins P., Johnson A., Tomkin G.H. Glycosylation of LDL is more sensitive to oxidation: Implications for the diabetic patient. Atherosclerosis. 102:1993;63-67.
16. Lyons T.J. Lipoprotein glycation and its metabolic consequences. Diabetes. 41(supp 2):1992;67-73.
17. Watanabe J., Wohltmann H.J., Klein R.L., Colwell J.A., Lopes-Virella M.F. Enhancement of platelet aggregation by low density lipoproteins from IDDM patients. Diabetes. 37:1988;1652-1657.
18. Lyons T.J. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol. 71:1993;26B-31B.
19. Hammes H.P., Martin S., Federlin K., Geisen K., Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 88:1991;11555-11558.
20. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes. 40:1991;1328-1334.
21. Kagihashi S., Kamijo M., Baba M., Yagihashi N., Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes. 41:1992;47-52.
22. Mills G.L., Tayleur C.E. The distribution and composition of serum lipoproteins in eighteen animals. Comp Biochem Physiol. 40B:1971;489-501.
23. Wills E.D. Lipid peroxide formation in microsomes. Biochem J. 113:1969;236-242.
24. Beavan M.A., Gordon J.W., Jacobsen S., Severs W.B. A specific and sensitive assay for aminoguanidine: Its application to a study of the disposition of aminoguanidine in animal tissues. J Pharmacol Exp Ther. 165:1969;14-22.
25. Warnick G.R., Nguyen T., Albers A.A. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem. 31:1985;217-222.
26. Holman R.L., McGill H.C., Strong J.P., Gerr J.C. Technics for studying atherosclerotic lesions. Lab Invest. 7:1958;42-47.
27. Makita Z., Vlassara H., Cerami A., Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem. 267:1992;5133-5138.
28. Zhu B.-Q., Sievers R.E., Sun Y.-P., Isenberg W.M., Parmley W.W. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol. 19:1992;246-255.
29. Fennessy P.A., Campbell J.H., Campbell G.R. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis. 106:1994;29-41.
30. Henry P.D., Bentley K.I. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest. 68:1981;1366-1369.
31. Vlassara H., Fuh H., Makita Z., Krungkrai S., Cerami A., Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA. 89:1992;12043-12047.
32. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li Y.M., Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA. 91:1994;11704-11708.
33. Huijberts M.S.P., Wolffenbuttel B.H.R., Crijns F.R.L., Nieuwenhuijzen Kruseman A.C., Bemelmans M.H.A., Struijker Boudier H.A.J. Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin diabetic rats. Diabetologia. 37:1994;10-14.
34. Hammes H.P., Brownlee M., Edelstein D., Salek M., Martin S., Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 37:1994;32-35.
35. Huijberts M.S.P., Wolfenbuttel B.H.R., Struijker Boudier H.A.J., Crijns F.R., Nieuwenhuizen Kruseman A.C., Poitevin P., Levy B.I. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest. 92:1993;1407-1411.
36. Sakata N., Meng J., Jimi S., Takebayashi S. Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Atherosclerosis. 116:1995;63-75.
37. Lee W.K., Bell J., Kilpatrick E., Hayes M., Lindop G.B.M., Dominiczak M.H. Collagen linked fluorescence in human atherosclerotic plaques. Atherosclerosis. 98:1993;219-227.
38. Palinski W., Koschinsky T., Butler S.W., Miller E., Vlassara H., Cerami A., Witzum J.L. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol. 15:1995;571-582.
39. Nakamura Y., Horii Y., Nishino T., Shiiki H., Sakaguchi Y., Kagoshima T., Dohi K., Makita A., Vlassara H., Bucala R. Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol. 143:1993;1649-1656.
40. Kume S., Takeya M., Mori T., Araki N., Suzuki H., Horiuchi S., Kodama T., Miyauchi Y., Takahashi K. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol. 147:1995;654-667.
41. Ritthaler U., Deng Y., Zhang Y., Greten J., Able M., Sido B., Allenberg G., Otto G., Roth H., Bierhaus A., Ziegler R., Schmidt A.-M., Waldherr R., Wahl P., Stern D.M., Nawroth P.P. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol. 146:1995;688-694.
42. Tames F.J., Mackness M.I., Arrol S., Laing I., Durrington P.N. Non-enzymatic glycation of apolipoprotein B in sera of diabetic and non-diabetic subjects. Atherosclerosis. 93:1992;237-244.
43. Witzum J.L., Mahoney E.M., Branks M.J., Fisher M., Elam R., Steinberg D. Nonenzymatic glycosylation of low-density lipoprotein alters its biological activity. Diabetes. 31:1982;283-291.
44. Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. 91:1994;9441-9445.
45. Hunt J.V., Dean R.T., Wolff S.P. Hydroxyl radical production and autoxidative glycosylation. Biochem J. 256:1988;205-212.
46. Yan S.D., Schmidt A.M., Anderson G.M., Zhang J., Brett J., Zou Y.S., Pinsky D., Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 269:1994;9889-9897.
47. Morel D.W., Hessler J.R., Chisolm G.M. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res. 24:1983;1070-1076.
48. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witzum J.L., Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA. 81:1984;3883-3887.
49. Soulis-Liparota T., Cooper M.E., Dunlop M., Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague Dawley rat. Diabetologia. 38:1995;387-394.
50. Sobey C., Brooks R.M., Heistad D.D. Evidence that expression of inducible nitric oxide synthase in response to endotoxin is augmented in atherosclerotic rabbits. Circ Res. 77:1995;536-543.
51. Corbett J.A., Tilton R.G., Chang K., Hasan K.S., Ido Y., Wang J.L., Sweetland M.S., Lancaster J.R., Williamson J.R., McDaniel M.L. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 41:1992;552-556.
52. Verbeuren T., Bonhomme E, Laubie M., Simonet S. Evidence for induction of nonendothelial NO synthase in aortas of cholesterol-fed rabbits. J Cardiovasc Pharmacol. 21:1993;841-845.
53. Cooke J.P., Singer A.H., Tsao P., Zera P., Rowan R.E. Antiatherogenic effects of L-arginine in the hypercholesterolaemic rabbit. J Clin Invest. 90:1992;1168-1172.
54. Cayatte A.J., Palacino J.J., Horten K., Cohen R.A. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb. 14:1994;753-759.
55. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest. 87:1991;432-438.